# Therapeutic Prospects of HMG-CoA Reductase Inhibitors, Atorvastatin and Rosuvastatin, in Osteoporotic Patients

> **NCT07717788** · NA · COMPLETED · sponsor: **Alkufa university\\collage of pharmacy** · enrollment: 65 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal
- Statin Therapy

## Interventions

- **DRUG:** Alendronate 70 mg tablets
- **DRUG:** Atorvastatin
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT07717788
- **Lead sponsor:** Alkufa university\\collage of pharmacy
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717788, "Therapeutic Prospects of HMG-CoA Reductase Inhibitors, Atorvastatin and Rosuvastatin, in Osteoporotic Patients". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07717788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*